Conditions: KRAS Mutant Solid Tumors
Interventions: Drug: TLN-372; Drug: TLN-372 in combination with cetuximab; Drug: TLN-372 in combination with pembrolizumab
Sponsors: Treeline Biosciences, Inc.
**RECRUITING NOW**
Interventions: Drug: TLN-372; Drug: TLN-372 in combination with cetuximab; Drug: TLN-372 in combination with pembrolizumab
Sponsors: Treeline Biosciences, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
